Antihypertensive treatment of patients with proteinuric renal diseases: Risks or benefits of calcium channel blockers?

Kidney International

Volumn 53, Issue 6, 1998, Pages 1559-1573

  Kloke, Heinrich J ^a   Branten, Amanda J ^a   Huysmans, Frans T ^a   Wetzels, Jack F ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antihypertensive drugs; Blood pressure; Dihydropyridine calcium channel blockers; Proteinuria; Renal failure

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ACUTE KIDNEY FAILURE; AUTOREGULATION; CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME INHIBITION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; PRIORITY JOURNAL; PROTEIN URINE LEVEL;

EID: 0031802190     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1998.00912.x     Document Type: Conference Paper

References (174)

1. KLAHR S, SCHREINER G, ICHIKAWA I: The progression of renal disease. N Engl J Med 318:1657-1666, 1988
2. BRENNER BM, MEYER TW, HOSTETTER TH: Dietary protein and the progressive nature of renal disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982
3. REMUZZI G, BERTANI T: Is glomerulosclerosis a consequence of altered permeability to macromolecules? Kidney Int 38:384-394, 1990
4. D'AMICO G: The clinical role of proteinuria. Am J Kidney Dis 17(Suppl 1):48-52, 1991
5. WILLIAMS JD, COLES GA: Proteinuria - a direct cause of renal morbidity? Kidney Int 45:443-450, 1994
6. BURTON CJ, WALLS J: Proximal tubular cell, proteinuria and tubulointerstitial scarring. Nephron 68:287-293, 1994
7. EDDY AA: Experimental insights into the tubulo-interstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 5:1273-1287, 1994
8. BRAZY PC, STEAD WW, FITZWILLIAM JF: Progression of renal insufficiency: Role of blood pressure. Kidney Int 35:670-674, 1989
9. WILLIAMS PS, FASS G, BONE JM: Renal pathology and proteinuria determine progression in untreated mild/moderate chronic renal failure. Q J Med 67:343-354, 1988
10. ALVESTRAND A, GUTIERREZ A, BUCHT H, BERGSTRÖM J: Reduction of blood pressure retards the progression of chronic renal failure in man. Nephrol Dial Transplant 3:624-631, 1988
11. KLAHR S, LEVEY AS, BECK GJ, CAGGIULA AW, HUNSICKER L, KUSEK JW, STRIKER G, FOR THE MODIFICATION OF DIET IN RENAL DISEASE STUDY GROUP: The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 330:877-884, 1994
12. PETERSON JC, ADLER S, BURKART JM, GREENE T, HEBERT LA, LAWRENCE G, HUNSICKER LG, KING AJ, KLAHR S, MASSRY SG, SEIFTER JL: Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 123:754-762, 1995
13. BAUMELOU A, BENTCHIKOU A, VRAY M, JOURDAN I, EUGENE M: Nitrendipine in patients with renal disease. J Cardiovasc Pharmacol 9(Suppl 4):S174-S177, 1987
14. BUHLER FR: Calcium antagonists as first-choice therapy for low-renin essential hypertension. (clinical conference) Kidney Int 36:295-305, 1989
15. MIMRAM A, RIBSTEIN J: Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases. Am J Hypertens 7:73S-81S, 1994
16. DEMARIE BK, BAKRIS GL: Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med 113: 987-988, 1990
17. WEIDMANN P, BOEHLEN LM, DE COURTEN M: Effects of different antihypertensive agents on human diabetic proteinuria. Nephrol Dial Transplant 8:582-584, 1993
18. WEIDMANN P, BOEHLEN LM, DE COURTEN M, FERRARI P: Antihypertensive therapy in diabetic patients. J Hum Hypert 6(Suppl 2):S23-S36, 1992
19. NORGAARD K, JENSEN T, FELDT-RASMUSSEN B: Effects of isradipine in type I (insulin-dependent) diabetic patients with albuminuria and normal blood pressure. J Hum Hypertens 6:145-150, 1992
20. BUHLER FR: Antihypertensive treatment according to age, plasma renin and race. Drugs 35:495-503, 1988
21. TRIGGLE DJ: Biochemical and pharmacological differences among calcium channel antagonists: Clinical implications, in Calcium Antagonists in Clinical Medicine, edited by EPSTEIN M, Philadelphia, Hanley & Belfus, Inc., 1992, p 1
22. MORI Y, MIKALA G, VARADI G, KOBAYASHI T, KOCH S, WAKAMORI M, SCHWARTZ A: Molecular pharmacology of voltage-dependent calcium channels. Jpn J Pharmacol 72:83-109, 1996
23. 2+ channel function and drug action. Trends Pharmacol Sci 16:43-49, 1995
24. ROSSIER MF, BURNAY MM, VALLOTTON MB, CAPPONI AM: Distinct functions of T- and L-type calcium channels during activation of bovine adrenal glomerulosa cells. Endocrinology 137:4817-4826, 1996
25. 2+ channel currents via activation of a G protein, Gi, Am J Physiol 271:C1340-C1349, 1996
26. TRIGGLE DJ: Pharmacologic and therapeutic differences among calcium channel antagonists: Profile of mihefradil, a new calcium antagonist. Am J Cardiol 78(Suppl 9A):7-12, 1996
27. DWORKIN LD, LEVIN RI, BENSTEIN JA, PARKER M, ULLIAN ME, KIM Y, FEINER HD: Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension. Am J Physiol 259:F598-F604, 1990
28. DWORKIN LD, FEINER HD, PARKER M, TOLBERT E: Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int 39:1112-1117, 1991
29. DWORKIN LD, BENSTEIN JA, PARKER M, TOLBERT E, FEINER HD: Calcium antagonists and converting enzyme inhibitors reduce renal injury by different mechanisms. Kidney Int 43:808-814, 1993
30. ELIAHOU HE, COHEN D, HERZOG D, SHECHTER P, SERBAN I, KAPULER S, SCHIBY G, GAVENDO S: The control of hypertension and its effect on renal function in rat remnant kidney. Nephrol Dial Transplant 3:38-44, 1988
31. KOBAYASHI S, HISHIDA A: Effects of a calcium antagonist, manidipine, on progressive renal injury associated with mild hypertension in remnant kidneys. J Lab Clin Med 125:572-580, 1995
32. KANNO Y, SUZUKI H, OKADA H, SARUTA T: Renal protective effects of amlodipine on partially nephrectomized spontaneously hypertensive rats fed a high-salt diet. J Cardiovasc Pharmacol 23:480-484, 1994
33. HARRIS DCH, HAMMOND WS, BURKE TJ, SCHRIER RW: Verapamil protects against progression of experimental chronic renal failure. Kidney Int 31:41-46, 1987
34. JARUSIRIPIPAT C, CHAN L, SHAPIRO JI, SCHRIER RW: Effect of long-acting calcium entry blocker (anipamil) on blood pressure, renal function and survival of uremic rats. J Pharmacol Exp Ther 260:243-247, 1992
35. NORDLANDER M, HAVU N: Effects of chronic felodipine treatment on renal function and morphology in SHR. Kidney Int 41(Suppl 36):S100-S105, 1992
36. FERRANTE F, ABBATE F, CIRIACO E, POLIDORI C, AMENTA F: Protective effect of nicardipine treatment on renal microanatomical changes in spontaneously hypertensive rats. Clin Exp Hypertens 16:415-429, 1994
37. SHUDO C, MASUDA Y, SUGITA H, FURUKAWA S, HAYASHI K, HIRATA H, TANAKA S, TOMITA K: Renal protective effect of efonidipine hydrochloride, a new calcium antagonist, in spontaneously hypertensive rats. Gen Pharmacol 25:1567-1575, 1994
38. ARAI T, KOBAYASHI S, NAKAJIMA T, HISHIDA A: Reduction of albuminuria by a calcium antagonist, manidipine, in rats with passive Heymann nephritis. Jap J Nephrol 36:1216-1220, 1994
39. SHIRAKURA S, SANO J, KARASAWA A, KUBO K: Protective effect of benidipine against the development of glomerular sclerosis in experimental nephrotic syndrome. Jpn J Pharmacol 59:461-467, 1992
40. GABER L, WALTON C, BROWN S, BAKRIS G: Effects of different antihypertensive treatments on morphologic progression of diabetic nephropathy in uninephrectomized does. Kidney Int 46:161-169, 1994
41. BROWN SA, WALLON CL, CRAWFORD P, BAKRIS GL: Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 43:1210-1218, 1993
42. JYOTHIRMAYI GN, REDDI AS: Effect of diltiazem on glomerular heparan sulfate and albuminuria in diabetic rats. Hypertension 21: 795-802, 1993
43. YOSHIDA K, KOHZUKI M, YASUJIMA M, KANAZAWA M, ABE K: Effects of benidipine, a calcium antagonist, on urinary kallikrein excretion and renal impairment in experimental diabetes. J Hypertens 14:215-222, 1996
44. AMANN K, NICHOLS C, TORNIG J, SCHWARZ U, ZEIER M, MALL G, RITZ E: Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure. Nephrol Dial Transplant 11:1003-1011, 1996
45. IRZYNIEC T, MALL G, GREBER D, RITZ E: Beneficial effect of nifedipine and moxonidine on glomerulosclerosis in spontaneously hypertensive rats. A micromorphometric study. Am J Hypertens 5:437-443, 1992
46. BRUNNER FP, THIEL G, HERMLE M, BOCK HA, MIHATSCH MJ: Long-term enalapril and verapamil in rats with reduced renal mass. Kidney Int 36:969-977, 1989
47. BRUNNER FP, BOCK HA, HERMLE M, THIEL G, MIHATSCH MJ: Control of hypertension by verapamil enhances renal damage in a rat remnant kidney model. Nephrol Dial Transplant 6:420-427, 1991
48. TOLINS JP, RAIJ L: Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. Hypertension 16:452-461, 1990
49. PODJARNY E, BERNHEIM JL, POMERANZ A, RATHAUS M, POMERANZ M, GREEN J, BERNHEIM J: Effect of timing of antihypertensive therapy on glomerular injury: Comparison between captopril and diltiazem. Nephrol Dial Transplant 8:501-506, 1993
50. JACKSON B, JOHNSTON CI: The contribution of systemic hypertension to progression of chronic renal failure in the rat remnant kidney: Effect of treatment with an angiotensin converting enzyme inhibitor or a calcium inhibitor. J Hypertens 6:495-501, 1988
51. WENZEL UO, TROSCHAU G, SCHOEPPE W, HELMCHEN U, SCHWIETZER G: Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension. Hypertension 20:233-241, 1992
52. VENIANT M, HEUDES D, CLOZEL J-P, BRUNEVAL P, MENARD J: Calcium blockade versus ACE inhibition in clipped and undipped kidneys of 2K-1C rats. Kidney Int 46:421-429, 1994
53. DWORKIN LD, TOLBERT E, RECHT PA, HERSCH JC, FEINER H, LEVIN RI: Effects of amlodipine on glomerular filtration, growth, and injury in experimental hypertension. Hypertension 27:245-250, 1996
54. GRIFFIN KA, PICKEN MM, BIDANI AK: Deleterious effects of calcium channel blockade on pressure transmission and glomerular injury in rat remnant kidneys. J Clin Invest 96:793-800, 1995
55. REAMS GP, VILLARREAL D, WU Z, WANG X, LUGER AM, BAUER JH: An evaluation of the renal protective effect of manidipine in the uninephrectomized spontaneously hypertensive rat. Am Heart J 125:620-625, 1993
56. REMUZZI A, IMBERTI O, PUNTORIEREI S, MALANCHINI B, MACCONI D, MAGRINI L, BERTANI T, REMUZZI G: Dissociation between antiproteinurie and anti-hypertensive effect of angiotensin converting enzyme inhibitors in rats. Am J Physiol 267:F1034-F1044, 1994
57. COOPER ME, RUMBLE JR, GIN T, LIM-JOON T: Diabetic renal microvascular disease: The role of hypertension and ACE-inhibitors. Clin Exp Pharmacol Physiol 19(Suppl 19):23-27, 1992
58. PERICO N, AMUCHASTEGUI CS, MALANCHINI B, BERTANI T, REMUZZI G: Angiotensin-converting enzyme inhibition and calcium channel blockade both normalize early hyperfiltration in experimental diabetes, but only the former prevents late renal structural damage. Exp Nephrol 2:220-228, 1994
59. ANDERSON S, RENNKE HG, BRENNER BM: Nifedipine versus fosinopril in uninephrectomized diabetic rats. Kidney Int 41:891-897, 1992
60. WHITTY MR, JACKSON B: Diabetic nephropathy in the rat: Differing renal effects of an angiotensin converting enzyme inhibitor and a calcium inhibitor. Diabetes Res 8:91-96, 1988
61. GRIFFIN KA, PICKEN M, BIDANI AK: Radiotelemetric BP monitoring, antihypertensives and glomeruloprotection in remnant kidney model. Kidney Int 46:1010-1018, 1994
62. BIDANI AK, GRIFFIN KA, PICKEN M, LANSKY DM: Continuous telemetric blood pressure monitoring and glomerular injury in the rat remnant kidney model. Am J Physiol 265:F391-F398, 1993
63. BIDANI AK, SCHWARTZ MM, LEWIS EJ: Renal autoregulation and vulnera-bility to hypertensive injury in remnant kidney. Am J Physiol 252:F1003-F1010, 1987
64. FLEMING JT, PAREKH N, STEINHAUSEN M: Calcium antagonists preferentially dilate preglomerular vessels of hydronephrotic kidney. Am J Physiol 253:F1157-F1163, 1987
65. LOUTZENHISER R, EPSTEIN M, HORTON C: Inhibition by diltiazem of pressure-induced afferent vasoconstriction in the isolated perfused kidney. Am J Cardiol 59:72A-75A, 1987
66. RODICIO JL, CAMPO C, RUILOPE LM: Renal effects of calcium antagonists. Nephrol Dial Transplant 10(Suppl 9):17-22, 1995
67. NAVAR LG, CHAMPION WJ, THOMAS CE: Effects of calcium channel blockade on renal vascular resistance responses to changes in perfusion pressure and angiotensin-converting enzyme inhibition in dogs. Circ Res 58:874-881, 1986
68. OGAWA N: Effect of nicardipine on the relationship of renal blood flow and of renal vascular resistance to perfusion pressure in dog kidney. J Pharm Pharmacol 42:138-140, 1990
69. CARMINES PK, MITCHELL KD, NAVAR LG: Effects of calcium antagonists on renal hemodynamics and glomerular function. Kidney Int 41(Suppl 36):S43-S48, 1942
70. KVAM FI, IVERSEN BM, OFSTAD J: Autoregulation of glomerular capillary pressure in SHR during successive reduction of systemic blood pressure with antihypertensive agents. (abstract) J Am Soc Nephrol 7:1552, 1996
71. PICKEN M, GRIFFIN K, BAKRIS G, BIDANI A: Differences in the anti-hypertensive and glomeruloprotective efficacies of calcium channel blockers in the remnant kidney model. (abstract) J Am Soc Nephrol 7:1586, 1996
72. BIDANI AK, GRIFFIN KA, PICKEN M: Preservation of renal autoregulation and not blockade of renal hypertrophy mediates the glomeruloprotection provided by a low protein diet in the remnant kidney model. (abstract) J Am Soc Nephrol 7:1577, 1996
73. CARMINES PK, NAVAR LG: Disparate effects of Ca channel blockade on afferent and efferent arteriolar responses to ANG II. Am J Physiol 256:F1015-F1020, 1989
74. CONGER JD, FALK SA: KCl and angiotensin responses in isolated renal arterioles: Effects of diltiazem and low-calcium medium. Am J Physiol 264:F134-F140, 1993
75. WENZEL UO, HELMCHEN U, SCHOEPPE W, SCHWIETZER G: Combination treatment of enalapril with nitrendipine in rats with renovascular hypertension. Hypertension 23:114-122, 1994
76. YOSHIDA Y, FOGO A, ICHIKAWA I: Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis. Kidney Int 35:654-660, 1989
77. MEYER TW, RENNKE HG: Progressive glomerular injury following limited infarction in the rat. Am J Physiol 254:F856-F862, 1988
78. LAX DS, BENSTEIN JA, TOLBERT E, DWORKIN LD: Effects of salt restriction on renal growth and glomerular injury in rats with remnant kidneys. Kidney Int 41:1527-1534, 1992
79. DWORKIN LD: Effects of calcium antagonists on glomerular hemodynamics and structure in experimental hypertension. Am J Kidney Dis 17:89-93, 1991
80. AMANN K, TORNIG J, NICHOLS C, ZEIER M, MALL G, RITZ E: Effect of ACE inhibitors, calcium channel blockers and their combination on renal and extrarenal structures in renal failure. Nephrol Dial Transplant 10(Suppl 9):33-38, 1995
81. BENSTEIN JA, FEINER HD, OHSUMI F, TOLBERT E, DWORKIN LD: Impact of salt restriction and calcium antagonists on renal hypertrophy, function and sclerosis in rats with remnant kidneys (RK) and established injury. (abstract) J Am Soc Nephrol 3:734, 1992
82. GOLIGORSKY MS, CHAIMOVITZ C, RAPAPORT J, GOLDSTEIN J, KOL R: Calcium metabolism in uremic nephrocalcinosis: Preventive effect of verapamil. Kidney Int 27:774-779, 1985
83. BAYLIS C, MITRUKA B, DENG, A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90:278-281, 1992
84. RIBEIRO MO, ANTUNES E, MUSCARA MN, DE NUCCI G, ZATZ R: Nifedipine prevents renal injury in rats with chronic nitric oxide inhibition. Hypertension 26:150-155, 1995
85. MCNALLY PG, FEEHALLY J: Pathophysiology of cyclosporin A nephrotoxicity: Experimental and clinical observations. Nephrol Dial Transplant 7:791-804, 1992
86. GANSEVOORT RT, DE ZEEUW D, DE JONG PE: Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease. Am J Kidney Dis 22:202-206, 1993
87. ROSSING P, HOMMEL E, SMIDT UM, PARVING, H-H: Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37:511-516, 1994
88. ABBOTT K, SMITH A, BAKRIS GL: Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. J Clin Pharmacol 36:274-279, 1996
89. AUGUST P, LENZ T, LARAGH JH: Comparative renal hemodynamic effects of lisinopril, verapamil, and amlodipine in patients with chronic renal failure. Am J Hypertens fi:148S-154S, 1993
90. BABA T, TOMIYAMA T, MURABAYASHI S, TAKEBE, K: Renal effects of nicardipine, a calcium antagonist, in hypertensive type 2 (non-insulin-dependent) diabetic patients with and without nephropathy. Eur J Clin Pharmacol 38:425-429, 1990
91. BABA T, MURABAYASHI S, TAKEBE K: Comparison of the renal effects of angiotensin converting enzyme inhibitor and calcium antagonist in hypertensive type 2 (non-insulin-dependent) diabetic patients with microalbuminuria: A randomised controlled trial. Diabetologia 32:40-44, 1989
92. BAKRIS GL, BARNHILL BW, SADLER R: Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney Int 41:912-919, 1992
93. BAKRIS GL, COPLEY JB, VICKNAIR N, SADLER R, LEURGANS S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50:1641-1650, 1996
94. BAKRIS GL, SMITH A: Effects of sodium intake on albumin excretion in patients with diabetic nephropathy treated with long-acting calcium antagonists. Ann Intern Med 125:201-204, 1996
95. BAKRIS GL: Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. (see comments) Ann Intern Med 112:707-708, 1990
96. BANNISTER KM, WEAVER A, CLARKSON AR, WOODROFFE AJ: Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol 111:184-192, 1995
97. BIANCHI S, BIGAZZI R, BALDARI G, CAMPESE VM: Microalbuminuria in patients with essential hypertension: Effects of several antihypertensive drugs. Am J Med 93:525-528, 1992
98. BIANCHI S, BIGAZZI R, BALDARI G, CAMPESE VM: Microalbuminuria in patients with essential hypertension. Effects of an angiotensin converting enzyme inhibitor and of a calcium channel blocker. Am J Hypertens 4:291-296, 1991
99. BIANCHI S, BIGAZZI R, BALDARI G, CAMPESE VM: Long-term effects of enalapril and nicardipine on urinary albumin excretion in patients with chronic renal insufficiency: A 1-year follow-up. Am J Nephrol 11:131-137, 1991
100. BIGAZZI R, BIANCHI S, BALDARI D, SGHERRI G, BALDARI G, CAMPESE VM: Long-term effects of a converting enzyme inhibitor and a calcium channel blocker on urinary albumin excretion in patients with essential hyperten-sion. Am J Hypertens 6:108-113, 1993
101. BILO H, KLUITMAN E, VAN BALLEGOOIE E, POTTER VAN LOON BJ, BAKKER K, MICHELS B, GANS R, DONKER A: Long term use of captopril or nifedipine in normotensive microalbuminuric patients with insulin-dependent diabetes mellitus. Diabetes Res 23:115-122, 1993
102. BOUHANICK B: Equivalent effects of nicardipine and captopril on urinary albumin excretion of type 2, non-insulin-dependent diabetic subjects with mild to moderate hypertension. Therapie 51:41-47, 1996
103. BRETZEL RG, BOLLEN CC, MAESER E, FEDERLIN KF: Nephroprotective effects of nitrendipine in hypertensive type I and type II diabetic patients. Am J Kidney Dis 21(Suppl 3):53-64, 1993
104. CHAN JC, COCKRAM CS, NICHOLLS MG, CHEUNG CK, SWAMINATHAN R: Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One year analysis. Brit Med J 305:981-985, 1992
105. CORCORAN JS, PERKINS JE, HOFFBRAND BI, YUDKIN JS: Treating hypertension in non-insulin-dependent diabetes: A comparison of atenolol, nifedipine, and captopril combined with bendrofluazide. Diabet Med 4:164-168, 1987
106. CREPALDI G, CARRARO A, BROCCO E, ADEZATI L, ANDREANI D, BOMPIANI G, BRUNETTI P, FEDELE D, GIORGINO R, GIUSTINA G, MENZINGER G, NAVALESI R, PAGANO G, TIENGO A, VILLA G, NOSADINI R: Hypertension and non-insulin- dependent diabetes. A comparison between an angiotensin-converting enzyme inhibitor and a calcium antagonist. Acta Diabetol 32:203-208, 1995
107. CRUICKSHANK JK, ANDERSON NM, WADSWORTH J, YOUNG SM, JEPSON E: Treating hypertension in black compared with white non-insulin dependent diabetics: A double blind trial of verapamil and metoprolol. Brit Med J 297:1155-1159, 1988
108. CRUICKSHANK JK, ANDERSON NM, WADSWORTH J, YOUNG SM, JEPSON E: Treating hypertensive diabetics: a comparison of verapamil and metoprolol in black and white patients. J Cardiovasc Pharmacol 10(Suppl 10):S85-S86, 1987
109. ERLEY CM, HAEFELE U, HEYNE N, BRAUN N, RISLER T: Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs. Hypertension 21:810-815, 1993
110. FERDER L, DACCORDI H, MARTELLO M, PANZALIS M, INSERRA F: Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 19(Suppl II):II-237-II-242, 1992
111. FIORETTO P, FRIGATO F, VELUSSI M, RIVA F, MUOLLO B, CARRARO A, BROCCO E, CIPOLLINA MR, ABATERUSSO C, TREVISAN M, ET AL: Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients. Am J Hypertens 5:837-846, 1992
112. FOGARI R, ZOPPI A, PASOTTI C, MUGELLINI A, LUSARDI P, LAZZARI P, CORRADI L: Comparative effects of ramipril and nitrendipine on albuminuria in hypertensive patients with non-insulin-dependent diabetes mellitus and impaired renal function. (see comments) J Hum Hypertens 9:131-135, 1995
113. GIORDANO M, SANDERS LR, CASTELLINO P, CANESSA ML, DEFRONZO RA: Effect of alpha-adrencrgic blockers. ACE inhibitors, and calcium channel antagonists on renal function in hypertensive non-insulin-dependent diabetic patients. Nephron 72:447-453, 1996
114. HAISA S, NORII T, TAKATORI E, GOTO A, MORJOKA S, UCHIDA K, HIMEI H: Effects of angiotensin-converting enzyme inhibitor (alacepril) and calcium antagonist (nicardipine) in hypertensive non-insulin-dependent diabetic patients with microalbuminuria. J Diabet Compl 5:162-164, 1991
115. HARTMANN A, LUND K, HOLDAAS H, FAUCHALD P, REISAETER A, BERG KJ: Contrasting short-term effects of nifedipine on glomerular and tubular functions in glomerulonephritic patients. J Am Soc Nephrol 5:1385-1390, 1994
116. HOLDAAS H, HARTMANN A, LIEN MG, NILSEN L, JERVELL J, FAUCHALD P, ENDRESEN L, DJOSELAND O, BERG, KJ: Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Intern Med 229:163-170, 1991
117. IKEDA T, NAKAYAMA D, GOMI T, SAKURAI J, YAMAZAKI T, YUHARA M: Captopril, an angiotensin I-converting enzyme inhibitor, decreases proteinuria in hypertensive patients with renal diseases. Nephron 52:72-75, 1989
118. INSUA A, RIBSTEIN J, MIMRAN A: Comparative effect of captopril and nifedipine in normotensive patients with incipient diabetic nephropathy. Postgrad Med J 64(Suppl 3):59-62, 1988
119. JENKINS DA, COWAN P, PATRICK AW, CLARKE BF: Renal responses to nifedipine and captopril in hypertensive insulin-dependent diabetic men: A randomized cross-over study. Nephrol Dial Transplant 8:200-205, 1993
120. JERUMS G, ALLEN TJ, TSALAMANDRIS C, COOPER ME: Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group. Kidney Int 41:904-911, 1992
121. JOSEFSBERG Z, ROSS SA, LEV RAN A, HWANG DL: Effects of enalapril and nitrendipine on the excretion of epidermal growth factor and albumin in hypertensive NIDDM patients. Diabetes Cure 18:690-693, 1995
122. JUNGMANN E, MALANYN M, MORTASAWI N, UNTERSTOGER E, HAAK T, PALITZSCH KD, SCHERBERICH J, SCHUMM DRAEGER PM, USADEL KH: Effect of 1-year treatment with nitrendipine versus enalapril on urinary albumin and alpha 1-microglobulin excretion in microalbuminuric patients with type 1 diabetes mellitus. A randomized, single-blind comparative study. Arzneimittelforschung 44:313-317, 1994
123. JUNGMANN E, SCHUMM DRAEGER PM, NICKELSEN T, SCHEUERMANN EH, SCHOFFLING K: [Long-term antihypertensive treatment in diabetes mellitus. Results with the calcium antagonist felodipine]. Fortschr Med 109:53-56, 1991
124. KIBRIYA MG, KHAN AR, RASHID HU, JASMINE F: Effect of captopril and nifedipine on kidney function and proteinuria in non-insulin-dependent diabetes mellitus (NIDDM) with nephropathy. Bangladesh Renal J 8:48-53, 1989
125. KLOKE HJ, WETZELS JFM, VAN HAMERSVELT HW, KOENE RAP, KLEINBLOESEM CH, HUYSMANS FTHM: Effects of nitrendipine and cilazapril on renal hemodynamics and albuminuria in hypertensive patients with chronic renal failure. J Cardiovasc Pharmacol 16:924-930, 1990
126. KLOKE HJ, WETZELS JFM, KOENE RAP, HUYSMANS FTM: Effects of low dose nifedipine on urinary protein excretion rate in patients with renal disease. J Hypertens 15(Suppl 4):S75, 1997
127. KUBO SH, CODY RJ, COVIT AB, FELDSCHUH J, LARAGH JH: The effects of verapamil on renal blood flow, renal function, and neurohormonal profiles in patients with moderate to severe hypertension. J Clin Hypertens 2:38S-46S, 1986
128. LENZ T, MULLER FB, SOTELO JE, LARAGH JH, AUGUST P: Hemodynamic responses to verapamil monotherapy in patients with renal disease. Am J Hypertens 4:939-943, 1991
129. MELBOURNE DIABETIC NEPHROPATHY STUDY GROUP: Comparison between perindopril and nifedipine in hypertensive and normotensive patients with microalbuminuria. Brit Med J 302:210-216, 1991
130. MICKISCH O, SCHMID M, MANN JF, HELDER T, BERGEN F, RAUTERBERG EW, RITZ E: [Calcium antagonists in chronic renal failure. Undesirable effects on glomerular hemodynamics?] Dtsch Med Wochenschr 113:1546-1548, 1988
131. MORLIN C, BAGLIVO H, BOEIJINGA JK, BRECKENRIDGE AM, CLEMENT D, JOHNSTON GD, KLEIN W, KRAMER R, LUCCIONI R, MEURER KA, RICHARDSON PJ, ROSENTHAL J, SIX R, WITZGALL H: Comparative trial of lisinopril and nifedipine in mild to severe essential hypertension. J Cardiovasc Pharmacol 9(Suppl 3):S49-52, 1987
132. NORGAARD K, JENSEN T, CHRISTENSEN P, FELDT RASMUSSEN B: A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension. Blood Press 2:301-308, 1993
133. MCDONNELL MJ, ROWE BR, LAWSON N, HORTON A, GYDE OH, BARNETT AH: Comparison of the effects of an angiotensin converting enzyme inhibitor and a calcium antagonist in hypertensive, macroproteinuric diabetic patients: A randomised double-blind study. J Hum Hypertens 7:333-339, 1993
134. OKAMURA M, KANAMAYAMA Y, NEGORO N, INOUE T, TAKEDA T: Long-term effects of calcium antagonists and angiotensin-converting enzyme inhibitors in patients with chronic renal failure of IgA nephropathy. Contrib Nephrol 90:161-165, 1991
135. PERSSON B, ANDERSSON OK, WYSOCKI M, HEDNER T, KARLBERG B: Calcium antagonism in essential hypertension: Effect on renal haemodynamics and microalbuminuria. J Intern Med 231:247-252, 1992
136. PICCOLI A, FAVARO E, PIVA M, BISETTO F, CALZAVARA P, ARDUINI R, NORDIO M, STOPPA F, RONCALI D, PILLON L: The progression rate of chronic renal failure with hypertension and proteinuria can be slowed by treatment with angiotensin converting enzyme inhibitors. Curr Ther Res 53:309-315, 1993
137. RANIERI G, ANDRIANI A, LAMONTANARA G, DE CESARIS R: Effects of lisinopril and amlodipine on microalbuminuria and renal function in patients with hypertension. Clin Pharmacol Ther 56:323-330, 1994
138. REAMS G, LAU A, KNAUS V, BAUER JH: The effect of nifedipine GITS on renal function in hypertensive patients with renal insufficiency. J Clin Pharmacol 31:468-472, 1991
139. REAMS GP, LAU A, BAUER JH: Short-term and long-term renal response to nifedipine monotherapy. Am J Hypertens 2:188-190, 1989
140. REAMS GP, LAU A, HAMORY A, BAUER JH: Amlodipine therapy corrects renal abnormalities encountered in the hypertensive state. Am J Kidney Dis 10:446-451, 1987
141. RICHARDSON PJ, MEANY B, BRECKENRIDGE AM, GRIMMER SF, JOHNSTON GD, KONDOWE G: Lisinopril in essential hypertension: A six month comparative study with nifedipine. J Hum Hypertens 1:175-179, 1987
142. ROMERO R, SALINAS I, LUCAS A, TEIXIDO J, AUDI L, SANMARTI A: Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients. Diabetes Res Clin Pract 17:191-198, 1992
143. RUGGENENTI P, MOSCONI L, BIANCHI L, CORTESI L, CAMPANA M, PAGANI G, MECCA G, REMUZZI G: Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients. Am J Kidney Dis 24:753-761, 1994
144. RUILOPE LM, ARAQUE A, LAHERA V, SUAREZ C: Antihypertensive effect of nitrendipine in the hypertensive patient with renal impairment. Ren Fail 15:359-363, 1993
145. RUILOPE LM, ALCAZAR JM, HERNANDEZ E, PRAGA M, LAHERA V, RODICIO JL: Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension. Kidney Int 45(Suppl 45):S171-S173, 1994
146. SCHMITZ A, PEDERSEN MM, MOLLER A, CHRISTIANSEN JS, MOGENSEN CE: Some aspects of antihypertensive and diuretic treatment in noninsulin-dependent diabetic patients. J Diahet Compl 4:79-81, 1990
147. SCHMITZ A, PEDERSEN MM, MOGENSEN CE: Effects of felodipine on urinary albumin excretion and metabolic control in hypertensive non-insulin-dependent diabetics. Am J Hypertens 3:611-617, 1990
148. SCHNACK C, CAPEK M, BANYAI M, KAUTZKY WILLER A, PRAGER R, SCHERNTHANER G: Long-term treatment with nifedipine reduces urinary albumin excretion and glomerular filtration rate in normotensive type 1 diabetic patients with microalbuminuria. Acta Diabetol 31:14-18, 1994
149. SIEWERT DELLE A, LJUNGMAN S, HARTFORD M, WIKSTRAND J: Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension. Addition of felodipine or ramipril to long-term treatment with beta-blockade. Am J Hypertens 8:113-123, 1995
150. SLATAPER R, VICKNAIR N, SADLER R, BAKRIS GL: Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 153:973-980, 1993
151. STORNELLO M, VALVO EV, SCAPELLATO L: Hemodynamic, renal, and humoral effects of the calcium entry blocker nicardipine and converting enzyme inhibitor captopril in hypertensive type II diabetic patients with nephropathy. J Cardiovasc Pharmacol 14:851-855, 1989
152. VELUSSI M, BROCCO E, FRIGATO F, ZOLLI M, MUOLLO B, MAIOLI M, CARRARO A, TONOLO G, FRESU P, CERNIGOI AM, FIORETTO P, NOSADINI R: Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 45:216-222, 1996
153. ZANETTI ELSHATER F, PINGITORE R, BERETTA PICCOLI C, RIESEN W, HEINEN G: Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. Am J Hypertens 7:36-45, 1994
154. ZUCCHELLI P, ZUCCALA A, BORGHI M, FUSAROLI M, SASDELLI M, STALLONE C, SANNA G, GAGGI R: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42:452-458, 1992
155. ZUCHELLI P, ZUCCALA A, GAGGI R: Comparison of the effects of ACE inhibitors and calcium channel blockers on the progression of renal failure. Nephrol Dial Transplant 10(Suppl 9):46-51, 1995
156. SHIHABI ZK, KONEN JC, O'CONNOR ML: Albuminuria vs urinary total protein for detecting chronic renal disorders. Clin Chem 37:621-624, 1991
157. GANSEVOORT RT, APPERLOO AJ, HEEG JE, DE JONG PE, DE ZEEUW D: The antiproteinuric effect of antihypertensive agents in diabetic nephropathy. Arch Intent Med 152:2137-2138, 1992
158. WEIDMANN P, SCHNEIDER M, BÖHLEN L: Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: An updated meta-analysis. Nephrol Dial Transplant 10(Suppl 9):39-45, 1995
159. SLUITER HE, WETZELS JFM, HUYSMANS FTHM, KOENE RAP: The natriuretic effect of the dihydropyridine calcium antagonist felodipine: A placebo-controlled study involving intravenous angiotensin II in normotensive volunteers. J Cardiovasc Pharmacol 10(Suppl 10): S154-S161, 1987
160. WETZELS JFM, WILTINK PG, HOITSMA AJ, HUYSMANS FTHM, KOENE RAP: Diuretic and natriuretic effects of nifedipine in healthy persons. Br J clin Pharmacol 25:547-553, 1988
161. KRUSELL LR, CHRISTENSEN CK, LEDERBALLE PEDERSEN O: Acute natriuretic effect of nifedipine in hypertensive patients and normotensive controls - A proximal tubular effect? Eur J Clin Pharmacol 32:121-126, 1987
162. GARINI G, MAZZI A, BUZIO C, MUTTI A, ALLEGRI L, SAVAZZI G, BORGHETTI A: Renal effects of captopril, indomethacin and nifedipine in nephrotic patients after an oral protein load. Nephrol Dial Transplant 11:628-634, 1996
163. NICHOLSON JP, RESNICK LM, LARAGH JH: The antihypertensive effect of verapamil at extremes of dietary sodium intake. Ann Intern Med 107:329-334, 1987
164. CAPPUCCIO FP, MARKANDU ND, MACGREGOR GA: Calcium antagonists and sodium halans: Effect of changes in sodium intake and the addition of a thiazide diuretic on the blood pressure lowering effect of nifedipine. J Cardiovasc Pharmacol 10(Suppl 10):S57-S60, 1987
165. REDON-MAS J, ABELLAN-ALEMAN J, ARANDRA-LARA P, DE LA FIGUERA-VON WICHMANN M, LUQUE-OTERO M, RODICIO-DIAZ JL, RUILOPE-URIOSTE LM, VELASCO-QUINTANA J: Antihypertensive activity of verapamil: Impact of dietary sodium. J Hypertens 11:665-671, 1993
166. MAN in 't Veld AJ: Calcium antagonists in hypertension. Am J Med 86(Suppl 4A):6-14, 1989
167. SCHOEN RE, FRISHMAN WH, SHAMOON H: Hormonal and metabolic effects of calcium channel antagonists in man. Am J Med 84:492-504, 1988
168. BLAU A, HERZOG D, SHECHTER P, SACHS D, ELIAHOU HE: Calcium channel blocker nisoldipine in chronic renal failure. Renal Failure 12:113-119, 1990
169. ELIAHOU HE, COHEN D, BEN-DAVID A, HERZOG D, SERBAN I, GAVENDO S, KAPULER S, KOGAN N, HELLBERG B: The calcium channel blocker nisoldipine delays progression of chronic renal failure in humans (preliminary communication). Cardiovasc Drugs Ther 1:523-528, 1988
170. MCCULLOCH TA, HARPER SJ, DONNELLY PK, MOORHOUSE J, BELL PRF, WALLS J, FEEHALLY J, FURNESS PN: Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A. J Clin Pathol 47:839-842, 1994
171. RUGGENENTI P, PERICO N, MOSCONI L, GASPARI F, BENIGNI A, AMUCHASTEGUI CS, BRUZZI I, REMUZZI G: Calcium channel blockers protect transplant patients from cyclosporin-induced daily renal hypoperfusion. Kidney Int 43:706-711, 1993
172. RODICIO JL, MORALES JM, RUILOPE LM: Lipophilic dihydropyridines provide renal protection from cyclosporin toxicity. J Hypertension 11(Suppl 6):S21-S25, 1993
173. PESAVENTO TE, JONES PA, JULIAN BA, CURTIS JJ: Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: Results of a prospective study. J Am Soc Nephrol 7:831-835, 1996
174. VALLANCE P, LEONE A, CALVER A, COLLIER J, MONCADA S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339:572-575, 1992